Compare Amphastar Pharmaceuticals Inc (AMPH) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Skyworks Solutions Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.42 (market cap $826.08M), while Skyworks Solutions Inc trades at $59.52 (market cap $9.08B). The key difference: Skyworks Solutions Inc is far larger — about 11× Amphastar Pharmaceuticals Inc's market cap, and Skyworks Solutions Inc pays a 4.7% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SWKS | |
|---|---|---|
Market Cap | $826.08M | $9.08B |
Sector | Health | Technology |
52-Week High | $30.81 | $83.40 |
52-Week Low | $16.87 | $52.50 |
Enterprise Value | $1.22B | $8.85B |
Dividend Yield | — | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SWKS trades at $60.36, up 0.68% on the day, with a bearish technical signal but bullish oscillators. The company reported Q1 2026 EPS of $1.15, beating estimates, and maintains a dividend. Revenue has trended down from $5.5B in 2022 to $4.1B in 2025, though net income margin remains positive at 8.93%. Recent news highlights potential in smartphone chips and AI infrastructure.
The outlook is mixed: strong analyst buy consensus (60%) and a $72.56 price target suggest upside, but declining revenue, legal investigations, and a bearish technical trend pose risks. The stock's valuation at a P/E of 25.16 appears reasonable if growth stabilizes, but investor caution is warranted amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
